VectorY Therapeutics B.V. is a clinical-stage biotechnology company headquartered in Amsterdam, the Netherlands, focused on developing vectorized antibody therapies for neurodegenerative diseases.
Founded in 2020, the company has created a proprietary platform that integrates highly selective intracellular antibodies with adeno-associated virus (AAV) vectors for one-time delivery to the central nervous system. This enables sustained antibody production inside target cells, addressing key limitations of conventional biologics in treating complex neurological conditions.
The pipeline features VTx-002 as the lead program, a first-in-class vectorized antibody targeting pathological TDP-43 implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases; it is advancing in the Phase 1/2 PIONEER-ALS trial. Additional candidates include programs for Huntington’s disease (targeting mutant HTT), frontotemporal dementia, Alzheimer’s disease (phosphorylated tau), and others such as Parkinson’s.
VectorY maintains R&D and manufacturing facilities in the Netherlands and has an office in Boston, United States. It is privately held and backed by venture capital investors including Forbion, EQT Life Sciences, Insight Partners, and the ALS Investment Fund. Recent financing includes a €74.5 million round with participation from the European Investment Bank.
The company positions itself as an innovator in AAV-enabled antibody therapies, aiming to deliver durable, potentially disease-modifying treatments for conditions with significant unmet medical needs.
Also known as VectoryTx.
None yet. When a new project in the record names VectorY as owner, partner or investor, it shows here.
The InvestEU-backed financing will support development of its vectorised antibody platform and expansion of its pipeline.
